CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...